{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T13:49:32Z","timestamp":1790603372930,"version":"4.1.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is an autoinflammatory disease caused by somatic variants in the <jats:italic>UBA1<\/jats:italic> gene that lead to severe systemic inflammation and myelodysplastic syndrome. Although no standard therapy has been established yet, azacitidine and bone marrow transplantation have been reported to be promising possibilities; however, the indications for these treatments are problematic and not necessarily applicable to all patients. We previously reported the results of short-term treatment with tocilizumab (TCZ) and glucocorticoids in three patients with VEXAS syndrome. In this paper, we report that the combination of TCZ and glucocorticoids allowed the patients to continue treatment for at least one year without significant disease progression. Glucocorticoids were able to be reduced from the start of TCZ. Adverse events were herpes zoster, skin ulceration after cellulitis, and decreased blood counts. The results suggest the significance of this treatment as a bridge therapy for the development of future therapies.<\/jats:p>","DOI":"10.3389\/fimmu.2022.901063","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T04:23:59Z","timestamp":1655094239000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":49,"title":["Case Report: Tocilizumab Treatment for VEXAS Syndrome With Relapsing Polychondritis: A Single-Center, 1-Year Longitudinal Observational Study In Japan"],"prefix":"10.3389","volume":"13","author":[{"given":"Yosuke","family":"Kunishita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Kirino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Tsuchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Takase-Minegishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusuke","family":"Yoshimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026834","article-title":"Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease","volume":"383","author":"Beck","year":"2020","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220089","article-title":"Pathogenic UBA1 Variants Associated With VEXAS Syndrome in Japanese Patients With Relapsing Polychondritis","author":"Tsuchida","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220876","article-title":"Tocilizumab in VEXAS Relapsing Polychondritis: A Single-Center Pilot Study in Japan","volume":"80","author":"Kirino","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213920","article-title":"Tocilizumab in Patients With Adult-Onset Still's Disease Refractory to Glucocorticoid Treatment: A Randomised, Double-Blind, Placebo-Controlled Phase III Trial","volume":"77","author":"Kaneko","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2021.03.177","article-title":"VEXAS Syndrome Chez Un Patient Aux Atteintes Inflammatoires Multiples Sans H\u00e9mopathie","volume":"42","author":"Cornut-Chauvinc","year":"2021","journal-title":"La Rev Med Interne"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab211","article-title":"VEXAS Syndrome in a Patient With Previous Spondyloarthritis With a Favourable Response to Intravenous Immunoglobulin and Anti-IL17 Therapy","volume":"60","author":"Magnol","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jaci.2021.05.014","article-title":"Adult-Onset Autoinflammation Caused by Somatic Mutations in UBA1: A Dutch Case Series of Patients With VEXAS","volume":"149","author":"Van Der Made","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.678927","article-title":"Case Report: VEXAS Syndrome: From Mild Symptoms to Life-Threatening Macrophage Activation Syndrome","volume":"12","author":"Staels","year":"2021","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010177","article-title":"Therapeutic Options in VEXAS Syndrome: Insights From a Retrospective Series","volume":"137","author":"Bourbon","year":"2021","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S0140-6736(21)01430-6","article-title":"Vacuoles, E1 Enzyme, X-Linked, Autoinflammatory, Somatic (VEXAS) Syndrome: Fevers, Myalgia, Arthralgia, Auricular Chondritis, and Erythema Nodosum","volume":"398","author":"Dehghan","year":"2021","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1182\/bloodadvances.2021004749","article-title":"Successful Allogeneic Hematopoietic Stem Cell Transplantation in Patients With VEXAS Syndrome: A 2-Center Experience","volume":"6","author":"Diarra","year":"2022","journal-title":"Blood Adv"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2021.06.006","article-title":"Clinical Heterogeneity of the VEXAS Syndrome: A Case Series","volume":"96","author":"Koster","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.800149","article-title":"Case Report: Genetic Double Strike: VEXAS and TET2-Positive Myelodysplastic Syndrome in a Patient With Long-Standing Refractory Autoinflammatory Disease","volume":"12","author":"Lotscher","year":"2021","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.4045\/tidsskr.21.0370","article-title":"A Man in His Sixties With Chondritis and Bone Marrow Failure","volume":"142","author":"Midtvedt","year":"2022","journal-title":"Tidsskr Nor Laegeforen"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2022.02.022","article-title":"Tocilizumab for Treatment of Cutaneous and Systemic Manifestations of Vacuoles, E1 Enzyme, X-Linked, Autoinflammatory, Somatic (VEXAS) Syndrome Without Myelodysplastic Syndrome","volume":"23","author":"Goyal","year":"2022","journal-title":"JAAD Case Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-152363","article-title":"Azacitidine for Patients With Vacuoles, E1 Enzyme, X-Linked, Autoinflammatory, Somatic Syndrome (VEXAS) and Myelodysplastic Syndrome: Data From the French VEXAS Registry","volume":"196","author":"Comont","year":"2021","journal-title":"Br J Haematol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1182\/bloodadvances.2021004749","article-title":"Successful Allogeneic Hematopoietic Stem Cell Transplantation in Patients With VEXAS Syndrome: A Two Center Experience","volume":"6","author":"Diarra","year":"2021","journal-title":"Blood Adv"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2102124","article-title":"Mutant UBA1 and Severe Adult-Onset Autoinflammatory Disease","volume":"384","author":"Diarra","year":"2021","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0902908","article-title":"Myelodysplastic Syndromes","volume":"361","author":"Tefferi","year":"2009","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.330","article-title":"Analysis of non-Relapse Mortality and Causes of Death Over 15 Years Following Allogeneic Hematopoietic Stem Cell Transplantation","volume":"51","author":"Tanaka","year":"2016","journal-title":"Bone Marrow Transplant"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.901063\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T04:24:03Z","timestamp":1655094243000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.901063\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,13]]},"references-count":20,"alternative-id":["10.3389\/fimmu.2022.901063"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.901063","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,13]]},"article-number":"901063"}}